MGTX -
MeiraGTx Holdings plc Ordinary Shares
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
8.03 0.11 (1.37%) |
--- |
--- |
--- |
--- |
0.11 (1.37%) |
--- |
--- |
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Earnings & Ratios
- Basic EPS:
- -0.48
- Diluted EPS:
- -0.48
- Basic P/E:
- -16.9583
- Diluted P/E:
- -16.9583
- RSI(14) 1m:
- 73.65
- VWAP:
- 8.12
- RVol:
- 0.5652
Events
Period |
Kind |
Movement |
Occurred At |
1m |
Price increase 1m |
8.22 +0.1 (+1.17%) |
Oct 15 10:48 |
Related News
MeiraGTx Sales Jump 1,133 Percent
Aug 14, 2025 12:31
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Aug 05, 2025 17:00
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
May 21, 2025 10:00
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight
Apr 22, 2025 17:00
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
Mar 04, 2025 15:55
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
May 08, 2024 21:10
MeiraGTx to Participate in Upcoming Investor Conferences
Apr 24, 2024 20:30
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
Apr 18, 2024 20:30
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
Mar 14, 2024 13:45
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
Mar 14, 2024 12:30